NEW YORK (AP) — Bermuda-based pharmaceutical company Warner Chilcott Ltd. said yesterday its third-quarter loss widened, hurt by higher selling costs and expenses related to its September public offering.Warner Chilcott, which focuses on women's health care and dermatology, reported a loss after paying preferred dividends of $101.9 million, or 95 cents per Class A share. A year ago, the company posted a loss of $94.7 million, or $1.07 per share.

Excluding a series of items, adjusted cash net income was $39.5 million.

Revenue jumped 51 percent to $194.7 million from $129 million last year, ahead of the $187.1 million expected by Wall Street. Cost of sales nearly doubled to $39.2 million from $21.6 million.